CAMBRIDGE, Mass. & SAN DIEGO, Calif. & DUBLIN--(BUSINESS WIRE)--Nov. 1, 2004--Biogen Idec Inc. (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) will host a conference call for the investment community at 8.00am ET / 1:00pm GMT on Wednesday, November 3, 2004. Peter Kellogg, Biogen Idec's CFO, and Shane Cooke, Elan's CFO, will review the accounting methodology for ANTEGREN® (natalizumab). The live webcast is accessible through Biogen Idec's website, www.biogenidec.com and Elan's website, www.elan.com.
About Biogen Idec
Biogen Idec creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.
About Elan
Elan is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing, selling and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. Elan's shares trade on the New York, London and Dublin Stock Exchanges.
CONTACT: Biogen Idec Inc.
Rob Jacobson, 617-679-3710
or
Elan Corporation, plc
Emer Reynolds, 353-1-709-4000
SOURCE: Biogen Idec Inc.
Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use